Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linc-ROR small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, In Vitro Transfection
01
Overview
linc-ROR small interfering RNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the long intergenic non-protein coding RNA, regulator of reprogramming (linc-ROR). In hepatocellular carcinoma (HCC), linc-ROR is known to facilitate tumor progression and resistance to doxorubicin by inducing the epithelial-mesenchymal transition (EMT) through interaction with the transcription factor TWIST1. By utilizing the RNAi pathway to degrade linc-ROR transcripts, this siRNA suppresses EMT and restores the sensitivity of HCC cells to chemotherapeutic agents. It is currently being investigated in preclinical research as a potential strategy to overcome chemoresistance in liver cancer.
- Other names
- linc-ROR siRNAsi-RORsiRNA targeting linc-ROR
Beyond the preview
Go deeper on linc-ROR small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linc-ROR small interfering RNA.